The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia

Insomnia Clinical Trial

— SOMNET  

Official title:

The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02821234
• Other study ID #: CHUBX 2016/05
• Status: Completed
• Phase: N/A
• First received: June 17, 2016
• Last updated: August 22, 2017
• Start date: September 1, 2016
• Est. completion date: April 3, 2017

Study information

• Verified date: August 2017
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

One-tenth of the population suffers from insomnia, increasing their risk on other health problems such as depression. Self-reported sleep quality only was historically leading for insomnia diagnosis, but more recently a state of 24-hour hyperarousal has been associated with insomnia, either physiological (increased heart rate, higher frequency EEG) or predominant cognitive-emotional hyperarousal (worry, rumination, repetitive thoughts). Strong evidence shows that those suffering from insomnia with physiological hyperarousal are at higher risk of short and long term severe health problems such as inflammation and hypertension than the group without physiological hyperarousal. The neurophysiological basis of these insomnia phenotypes has however barely been investigated, although its results can have major consequences for how this limiting condition will be treated.

To support the development of a differential diagnosis of insomnia, structural and functional brain connectivity in insomnia patients with different levels of hyperarousal will be investigated and related to sleep variables. Investigators will compare the insomnia group to a normal sleeping control group. Investigators expect that the emotion processing circuit (amygdala-ventromedial prefrontal cortex) is a) more affected in insomniacs compared to normal sleeping controls and b) the directionality of this effect to depend on the level and type of hyperarousal in insomniacs. Further, investigators expect c) amygdala activity to be positive correlated with physiological hyperarousal level and d) prefrontal activity to be positively correlated with cognitive-emotional hyperarousal level. Investigators expect a higher physiological hyperarousal level to be reflected in affected afferent pathways of the amygdala towards the ventromedial prefrontal cortex and investigators expect higher cognitive-emotional hyperarousal to be related to affected efferent pathways from the ventromedial prefrontal cortex to the amygdala. Investigators expect sleep quality to play a mediating role in both types of hyperarousal and their brain activation patterns in insomnia patients and normal sleeping controls.

These data can lead to the definition of new insomnia phenotypes and to new customized and effective insomnia treatment, focused not only on improving sleep but also on changing dysfunctional hyperarousal levels that currently put insomniacs at risk of numerous severe health problems.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 3, 2017
• Est. primary completion date: April 3, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Insomnia group: patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning.

• control group: no self-reported sleep problems in the last 2 months.

• 20-50 years old.

• Male or female.

• having given written informed consent to participate in the research project.

Exclusion Criteria:

• Night and shift-workers.

• Psychiatric disorder: clinical mood disorder, anxiety disorder, psychosis, bipolar disorder.

• For insomnia group: all sleep disorders other than persistent insomnia.

• For control group: all sleep disorders.

• Progressive neurological diseases that include restless legs syndrome.

• Cardiovascular disease other than treated hypertension.

• Unstable respiratory or endocrinological diseases.

• Drug addiction, alcohol addiction during the previous 6 months.

• Having undertaken trans-meridian travel (± 3H) in the previous 1 month.

• Pregnant or lactating women.

• Chronic pain.

• Hypnotic and psychotropic medication taking or stopped less than 5 half-life periods of molecules before screening V0.

• Patient participating to any other interventional study.

• For MRI: presence of a ferromagnetic foreign body (in particular certain intracranial clips, certain cardiac valves, intraocular foreign body, or subject having worked with metals), the presence of an implanted pacemaker, subject with cardiac or brain valves of ventricular derivation (risk of maladjustment), claustrophobia.

Related Conditions & MeSH terms

• Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Other:
• MRI

Locations

Country	Name	City	State
France	CHU de Bordeaux	Bordeaux

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Bordeaux	Institut des Maladies Neurodégénératives (UMR5293)

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resting state intrinsic connectivity within the emotion processing network by MRI		During Visit V2 (study termination), up to 3 month after consent signature
Secondary	Total sleep time obtained by actimetry		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	Sleep efficiency obtained by actimetry		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	Wake after sleep onset obtained by actimetry		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	Sleep latency obtained by actimetry		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	Total sleep time obtained by sleep diary		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	Sleep efficiency obtained by sleep diary		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	Wake after sleep onset obtained by sleep diary		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	sleep latency obtained by sleep diary		During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Secondary	Questionnaire regarding sleep problems : Pittsburgh Sleep Questionaire (PSQ)		During Pre-inclusion Visit, at consent signature
Secondary	Questionnaire regarding sleep problems : Insomnia Severity Index (ISI)		During Pre-inclusion Visit, at consent signature
Secondary	Questionnaire regarding depression : Beck Depression Inventory (BDI)		During Pre-inclusion Visit, at consent signature
Secondary	Questionnaire regarding anxiety : Beck Anxiety Inventory (BAI)		During Pre-inclusion Visit, at consent signature
Secondary	Questionnaire regarding arousal : Arousal Predisposition Scale (APS)		During Inclusion Visit, up to 1 month after consent signature
Secondary	Questionnaire regarding sleep reactivity : Ford Insomnia Response to Stress Test (FIRST)		During Inclusion Visit, up to 1 month after consent signature
Secondary	Questionnaire regarding presleep arousal state : Presleep State Arousal Scale (PSAS)		During Visit V2 (study termination), up to 3 month after consent signature
Secondary	Questionaire regarding emotional state : Positive and Negative Affect Schedule (PANAS)		During Visit V2 (study termination), up to 3 month after consent signature